Systems and methods for immunomodulation of mucosal-associated invariant T cells

Patent metadata

Field	Value
Publication number	US-12152252-B2
Application number	US-201816480273-A
Country	US
Kind code	B2
Filing date	Jan 23, 2018
Priority date	Jan 23, 2017
Publication date	Nov 26, 2024
Grant date	Nov 26, 2024

Abstract

Systems and methods to modulate the function of mucosal-associated invariant T (MAIT) cells in the absence of a T cell receptor (TCR) signal are described. The systems and methods can be used to elucidate the function of MAIT cells to assess potential therapeutic strategies for conditions associated with inflammation.

First claim

What is claimed is:

1. A method comprising:
inducing expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4) on mucosal-associated invariant T (MAIT) cells in the absence of a T cell receptor (TCR) signal by incubating the MAIT cells in a single culture media with an effective amount of each of interleukin (IL)-12, IL-15, IL-18, and an anti-MR1 antibody for an effective duration of time, thereby inducing the expression of the CTLA-4 on the MAIT cells in the absence of the TCR signal; and
measuring the expression of the CTLA-4 on the MAIT cells after the inducing.

2. The method of claim 1 , wherein the effective amount of IL-12 is 100 ng/ml, the effective amount of IL-15 is 100 ng/ml, and the effective amount of IL-18 is 100 ng/mL.

3. The method of claim 1 , wherein the effective amount of the anti-MR1 antibody is 50 μg/mL.

4. The method of claim 1 , wherein the effective duration of time is 24 hours.

5. The method of claim 1 , wherein the effective duration of time is at least 24 hours.

6. The method of claim 1 , wherein the MAIT cells are in a population of mononuclear cells.

7. The method of claim 1 , wherein the MAIT cells are CD3 + CD4 − CD8 + Vα7.2 + CD161 hi .

8. The method of claim 1 , wherein the MAIT cells are CD8 + CD161 hi CCR6 hi CD62L lo .

9. The method of claim 1 , wherein the single culture media comprises RPMI 1640 supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin sulfate, and 10% FBS.

Assignees

• Fred Hutchinson Cancer Center

Inventors

• Prlic Martin
• Berkson Julia
• Slichter Chloe

Classifications

• G01N2333/70596

  Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705 · CPC title

• G01N33/68

  involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)} · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q1/6876

  Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes · CPC title

• C12N2501/998

  Proteins not provided for elsewhere · CPC title